(Q27777362)

13 November 2016

title

MEK1 mutations confer resistance to MEK and B-RAF inhibition (English)

1 reference

PubMed

PubMed publication ID

13 November 2016

15

0 references

Levi A Garraway

16

object named as

Levi A Garraway

0 references

Nathanael Gray

13

object named as

Nathanael S Gray

0 references

author name string

Caroline M Emery

1

0 references

Krishna G Vijayendran

2

0 references

Marie C Zipser

3

0 references

Allison M Sawyer

4

0 references

Lili Niu

5

0 references

Jessica J Kim

6

0 references

Charles Hatton

7

0 references

Rajiv Chopra

8

0 references

Patrick A Oberholzer

9

0 references

Maria B Karpova

10

0 references

Laura E MacConaill

11

0 references

Jianming Zhang

12

0 references

William R Sellers

Proceedings of the National Academy of Sciences of the United States of America

14

0 references

language of work or name

English

0 references

publication date

1 December 2009

0 references

published in

0 references

volume

106

0 references

issue

48

0 references

page(s)

20411-6

0 references

cites work

Crystal structures of MEK1 binary and ternary complexes with nucleotides and inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2777185

Accurate whole human genome sequencing using reversible terminator chemistry

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2777185

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2777185

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2777185

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2777185

Mutations of the BRAF gene in human cancer

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2777185

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2777185

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2777185

BRAF mutation predicts sensitivity to MEK inhibition

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2777185

Cancer. Addiction to oncogenes--the Achilles heal of cancer

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2777185

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2777185

(V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2777185

Spectrum of MEK1 and MEK2 gene mutations in cardio-facio-cutaneous syndrome and genotype-phenotype correlations

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2777185

Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2777185

Modeling genomic diversity and tumor dependency in malignant melanoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2777185

Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2777185

Mutation analysis of BRAF, MEK1 and MEK2 in 15 ovarian cancer cell lines: implications for therapy

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2777185

Cardio-facio-cutaneous and Noonan syndromes due to mutations in the RAS/MAPK signalling pathway: genotype-phenotype relationships and overlap with Costello syndrome.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2777185

AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in precl

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2777185

Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2777185

CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK)

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2777185

Cell signaling and cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2777185

Identification of a novel mitogen-activated protein kinase kinase activation domain recognized by the inhibitor PD 184352.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2777185

Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group

29 September 2017

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.0905833106

Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.0905833106

Biochemical characterization of novel germline BRAF and MEK mutations in cardio-facio-cutaneous syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.0905833106

Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.0905833106

High-throughput oncogene mutation profiling in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.0905833106

21 January 2018

Identifiers

DOI

10.1073/PNAS.0905833106

1 reference

release_e4hvjcspdnaulldln4ppcg22pm

0 references

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/e4hvjcspdnaulldln4ppcg22pm

mapped directly with Wikidata item

24 November 2022

based on heuristic

1503785

1 reference

1 reference

1503785

PubMed publication ID

19915144

1 reference